ValueAct Capital 13F holdings, Q3 2009
Holdings as of September 30, 2009 · filings on SEC EDGAR · latest filing →
ValueAct Capital disclosed 12 US equity positions worth $2.4bn in its Q3 2009 13F filing. The largest position was VALEANT PHARMACEUTICALS INTL at 20.6% of the reported book, followed by SARA LEE CORP and IT. Against the Q2 2009 filing, it opened 3 new positions, added to 3 and reduced 3 among the top 12 holdings.
What did ValueAct Capital own in Q3 2009? Top 12 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2009 |
|---|---|---|---|---|---|---|---|
| 1 | VALEANT PHARMACEUTICALS INTL | 20.6% | $498.8m | 17,775,903 | 4% | added | |
| 2 | SARA LEE CORP | 16.1% | $388.9m | 34,909,567 | 0% | held | |
| 3 | IT GARTNER GROUP INC NEW-CL A | Technology | 15.7% | $379.8m | 20,790,013 | 0% | held |
| 4 | BFH ALLIANCE DATA SYSTEM CORP | Financial Services | 8.5% | $205.4m | 3,362,318 | -9% | reduced |
| 5 | MDS INC | 7.8% | $189.3m | 23,107,700 | 0% | held | |
| 6 | THOMSON REUTERS CORP | 7.8% | $189.0m | 5,630,518 | -54% | reduced | |
| 7 | WILLIS GROUP HOLDINGS LTD | 6.8% | $163.3m | 5,786,010 | 68% | added | |
| 8 | EFX EQUIFAX INC | Industrials | 4.7% | $112.4m | 3,857,457 | -60% | reduced |
| 9 | C R BARD INC | 4.6% | $111.0m | 1,411,700 | – | new | |
| 10 | IMMUCOR INC | 2.7% | $65.8m | 3,715,200 | 86% | added | |
| 11 | VRSN VERISIGN INC | Technology | 2.5% | $59.3m | 2,504,700 | – | new |
| 12 | GEN-PROBE INC NEW | 2.2% | $53.1m | 1,280,600 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.